VeinWay

Advanced Vein Blockage Crossing Tools

Health Tech & Life Sciences
Active
Series A Or Yehuda, Israel Founded 2020
Last updated 2026-06-18
Total raised
$7.4M
Last: 2023-11
Stage
Series A
Founded
2020
Headcount
6
HQ
Or Yehuda, Israel
Sector
Health Tech & Life Sciences

About

VeinWay is focused on developing a novel technology for crossing chronically occluded veins.

VeinWay's Traversa delivers the first dedicated device designed for venous recanalization that will improve outcomes and allow physicians to reliably, safely and easily complete endovascular procedures in a timely manner for the effective treatment of CVOs. The Traversa is an enabling technology which will disrupt the market by democratizing physician access to the treatment of CVOs. The innovation has a significantly different approach compared to existing solutions on the market or that are currently in development. All other solutions are either off-label tools that have a high risk of perforation, or standard crossing tools with no specific indication or features for venous recanalization. Physicians use them as workarounds when the procedure fails with standard guidewires. In contrast, Traversa is the first tool designed specifically for crossing CVOs, allowing for an unparalleled level of control that will enable interventional radiologists and vascular surgeons to cross occlusions every time.

VeinWay was created as part of the entrepreneur in residence program with the MEDX Xelerator, which supports and helps inventors and entrepreneurs cultivate early-stage ideas addressing complex unmet clinical needs.

Funding history · 4 rounds · $7.4M total

Q&A

What is VeinWay's primary focus?
VeinWay is focused on developing novel technology for crossing chronically occluded veins, specifically with its Traversa device designed for venous recanalization.
When was VeinWay founded?
VeinWay was founded in November 2020.
What is VeinWay's total funding to date?
VeinWay has raised a total of $7,435,000 USD.
Which investors participated in VeinWay's September 2023 funding round?
In September 2023, VeinWay received funding from Consensus Business Group (CBG) and Boston Scientific.
What was VeinWay's most recent funding round?
VeinWay's most recent funding round occurred in November 2023, raising $5,000,000 USD.
Who are the co-founders of VeinWay?
The co-founders of VeinWay are Jordan Pollack (Co-founder & CEO) and Ben Friesem (Co-founder & CTO).
What is the current product stage of VeinWay's technology?
VeinWay's product is currently in the clinical trial stage.

Team · 2

Founder · Co-founder & CEO
LinkedIn ↗
Founder · Co-founder & CTO
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Target customers
Healthcare & Life SciencesHealthcareProviders
Business model
B2B

Highlights

1 PatentsVerified

Tags

medical-devicescardiologyvasculartreatmentsmedical-technologiescardiovascular
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)